Mereo BioPharma (MREO) Notes Payables (2017 - 2024)

Mereo BioPharma (MREO) posted quarterly Notes Payables of $5.5 million for Q4 2024, little changed quarter-over-quarter from $5.6 million in Q3 2024.

Mereo BioPharma (MREO) Notes Payables (2017 - 2024) Analysis & Trends

Mereo BioPharma (MREO) has reported Notes Payables for 7 consecutive years, with $5.5 million the latest figure, recorded in Q4 2024.

In Q4 2024, Notes Payables changed N/A year-over-year to $5.5 million; the TTM figure through Dec 2024 stood at $5.5 million (changed N/A YoY), while the FY2024 annual figure was $5.5 million, changed N/A from the prior year.
Notes Payables steadied at $5.5 million in Q4 2024 per MREO's latest filing, from $5.6 million in the prior quarter.
Across five years, Notes Payables topped out at $16.5 million in Q2 2020 and bottomed at $4.6 million in Q1 2024.
Historically, Notes Payables has averaged $7.9 million across 4 years, with a median of $5.5 million in 2024.
Annual changes were most pronounced in 2020 — Notes Payables soared 59.71% — and 2024, when it decreased 5.86%.
Mereo BioPharma's Notes Payables stood at $16.5 million in 2020, then slipped by 21.0% to $13.0 million in 2022, then tumbled by 59.71% to $5.2 million in 2023, then grew by 5.67% to $5.5 million in 2024.
Business Quant data shows MREO's Notes Payables at $5.5 million in Q4 2024, $5.6 million in Q3 2024, and $4.9 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.35 Bn	131.49 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.24 Bn	78.25 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.08 Bn	1.37 Bn
4	Moderna	58.83 Bn	53.69 Bn	52.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn
8	Insmed	27.50 Bn	26.34 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.44 Bn	-
10	Mereo BioPharma	47.51 Mn	47.51 Mn	-

Download Data